FDA Approves MammoSite Radiation Therapy System for Use With Lumpectomy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

ROCKVILLE, Maryland-The FDA has approved the MammoSite Radiation Therapy System (Proxima Therapeutics, Alpharetta, Georgia), to deliver adjuvant radiation therapy after breast-conserving surgery for patients with early-stage disease. The device is designed to irradiate the surgical site with minimal exposure to surrounding tissue. It consists of a hollow catheter, to which an inflatable balloon is attached. After surgery, the device is implanted, the balloon inflated, and a radiation source is placed in the catheter. The balloon centers the radiation source at the wound site. After a series of treatments, generally extending over several days, the catheter is withdrawn.

ROCKVILLE, Maryland—The FDA has approved the MammoSite Radiation Therapy System (Proxima Therapeutics, Alpharetta, Georgia), to deliver adjuvant radiation therapy after breast-conserving surgery for patients with early-stage disease. The device is designed to irradiate the surgical site with minimal exposure to surrounding tissue. It consists of a hollow catheter, to which an inflatable balloon is attached. After surgery, the device is implanted, the balloon inflated, and a radiation source is placed in the catheter. The balloon centers the radiation source at the wound site. After a series of treatments, generally extending over several days, the catheter is withdrawn.

FDA approval was based on data from 25 women treated at eight centers. The FDA required Proxima to include a warning in its labeling that clinical trials have not proven MammoSite to be safe and effective as a replacement for whole breast irradiation in women undergoing mammography.

Recent Videos
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
2 experts are featured in this series.
Related Content